Sinonasal mucormycosis and liposomal amphotericin B: A quest for dose optimization

Area of Science:

• Mycology
• Infectious Diseases
• Clinical Pharmacology

Background:

• Sinonasal mucormycosis is a severe fungal infection requiring prompt treatment.
• Liposomal amphotericin B (LAmB) is the preferred antifungal, but optimal dosage remains unclear.
• Early diagnosis, antifungal therapy, and surgery are crucial for management.

Purpose of the Study:

• To determine the optimal dose of liposomal amphotericin B (LAmB) for treating sinonasal mucormycosis.
• To identify factors influencing treatment outcomes in patients with sinonasal mucormycosis.

Main Methods:

• Retrospective study of 30 patients with sinonasal mucormycosis treated with LAmB.
• Logistic regression analysis to correlate LAmB dose and other parameters with clinical and radiological outcomes.
• Monitoring of renal and electrolyte parameters to assess LAmB toxicity.

Main Results:

• The logistic regression model showed good fit (Pearson=0.999, Deviance=0.995) and significant likelihood ratio (0.001).
• Overall model prediction was 83.3%, but no statistically significant correlation was found between mean LAmB dose (82.2 ± 13.02 mg/kg) and patient outcomes.
• No significant correlation was observed between LAmB dose and changes in urea, creatinine, or potassium levels.

Conclusions:

• Patient-specific factors significantly influence sinonasal mucormycosis outcomes.
• The optimal LAmB dose requires individualized adjustment based on clinical experience.
• Further well-designed studies are needed to establish definitive LAmB dosage guidelines.